Overview

Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The study is to determine if NHL patients mobilized with G-CSF (10 µg/kg/day [GRAN® only]) plus 0.24 mg/kg/day of plerixafor are more likely to achieve a target number of ≥5 × 10^6 CD34+ cells/kg in 4 or fewer days of apheresis than NHL patients mobilized with G-CSF plus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

JM 3100
Lenograstim
Plerixafor
Sargramostim